One of the cancer-related Healthy People 2010 goals is to decrease deaths from cancer of the cervix in the U.S. from 3/100,000 to 2/100,000. The basis for this goal is the tremendous impact of the Papanicolaou (Pap) test in reducing mortality from this once common and devastating cancer. Over the past 50 years, U.S. death rates have dropped by 75%, and the target is certainly possible if screening and appropriate follow-up can be extended to all women.Given the remarkable effectiveness of cervical screening in lowering mortality, we must still recognize that the Pap test is only moderately accurate. Fortunately, the long preinvasive phase of cervical cancer and the successful public health initiatives that foster regular follow-up examinations lead to repeated opportunities to discover the neoplasm when it is curable. The NCCN Cervical Screening Clinical Practice Guidelines in Oncology provide a valuable roadmap for ensuring that appropriate steps are taken when routine examination shows abnormalities. A third factor leading to success has been the concerted educational and quality assurance programs to minimize laboratory variation and error.Therefore, noting the two major advances in the science of cervical screening in the past several years is gratifying: the use liquid-based cytology (LBC) to process Pap specimens and the use of human papillomavirus (HPV) testing to help guide the interpretation abnormal tests.In his review of the extensive trials comparing conventional Pap and LBC preparations, Cox notes that the new modality appears to be more sensitive in finding both low- and high-grade squamous...
If the inline PDF is not rendering correctly, you can download the PDF file here.
Rodger J. Winn is the Editor-in-Chief of JNCCN. His past positions include Associate Professor of Clinical Medicine at the University of Texas M. D. Anderson Cancer Center. Dr. Winn received his medical degree from Jefferson Medical College of Philadelphia. His postgraduate training includes an internship and residency at Jefferson Medical College, and he also completed a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York. He is board certified in internal medicine and holds subspecialty certification in oncology.
The ASCUS-LSIL Triage Study (ALTS) group. Results of a randomized trial in the management of cytology interpretations of atypical squanous cells of undetermined significance. Am J Obstet Gynecol2003;188:1383–1392.
The ASCUS-LSIL Triage Study (ALTS) group. Results of a randomized trial in the management of cytology interpretations of atypical squanous cells of undetermined significance. 2003;188:1383–1392.